NASDAQ:OVAS - OvaScience Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.97 -0.01 (-1.02 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$0.98
Today's Range$0.97 - $0.99
52-Week Range$0.71 - $1.96
Volume2,398 shs
Average Volume157,784 shs
Market Capitalization$35.40 million
P/E Ratio-0.75
Dividend YieldN/A
Beta3.12
OvaScience logoOvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman's egg production by isolating a woman's own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman's own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Receive OVAS News and Ratings via Email

Sign-up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVAS
CUSIPN/A
Phone617-500-2802

Debt

Debt-to-Equity RatioN/A
Current Ratio11.76
Quick Ratio11.76

Price-To-Earnings

Trailing P/E Ratio-0.75
Forward P/E Ratio-0.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales119.61
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book0.54

Profitability

EPS (Most Recent Fiscal Year)($1.32)
Net Income$-50,970,000.00
Net Margins-14,580.87%
Return on Equity-58.43%
Return on Assets-51.55%

Miscellaneous

Employees36
Outstanding Shares35,760,000

OvaScience (NASDAQ:OVAS) Frequently Asked Questions

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience Inc (NASDAQ:OVAS) issued its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.19) earnings per share for the quarter. The biotechnology company earned $0.07 million during the quarter. OvaScience had a negative return on equity of 58.43% and a negative net margin of 14,580.87%. View OvaScience's Earnings History.

When is OvaScience's next earnings date?

OvaScience is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for OvaScience.

What price target have analysts set for OVAS?

2 brokers have issued 1-year target prices for OvaScience's stock. Their forecasts range from $15.00 to $15.00. On average, they expect OvaScience's stock price to reach $15.00 in the next twelve months. View Analyst Ratings for OvaScience.

What are Wall Street analysts saying about OvaScience stock?

Here are some recent quotes from research analysts about OvaScience stock:
  • 1. HC Wainwright analysts commented, "Refocus on Science Should Aid in the Long Term; Reit Buy Incremental progress as the company seeks to capitalize upon its internal expertise in cell biology. On yesterday’s 4Q17 call, the company provided an update on the OvaPrime and OvaTure programs as management pivoted to a R&D-focused strategy. We think the key takeaways are two-fold: (1) the interim data from the first 20 patients in the Phase 1 trial of OvaPrime appear to deliver bittersweet news. The safety data look clean, but no strong signals were observed on the secondary endpoints that could suggest efficacy. As a result, this trial has terminated patient enrollment, and per management, the company will advance OvaPrime directly to a Phase 1b/2a study in 2H18 with an improved cell processing technique to hopefully improve efficacy." (3/16/2018)
  • 2. According to Zacks Investment Research, "OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2018)

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:
  • Dr. Michelle Dipp, Co-Founder & Advisor (Age 42)
  • Mr. Richard H. Aldrich, Co-Founder & Lead Independent Director (Age 64)
  • Dr. Christopher A. Kroeger, CEO, Pres, Sec. & Director (Age 50)
  • Dr. Jonathan L. Tilly Ph.D., Co-Founder and Advisor (Age 55)
  • Mr. Jonathan Gillis, Sr. VP of Fin. & Treasurer (Age 37)

Has OvaScience been receiving favorable news coverage?

News stories about OVAS stock have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OvaScience earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are OvaScience's major shareholders?

OvaScience's stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (4.09%), Wells Fargo & Company MN (1.33%) and Franklin Resources Inc. (1.00%). View Institutional Ownership Trends for OvaScience.

Which major investors are selling OvaScience stock?

OVAS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc.. View Insider Buying and Selling for OvaScience.

Which major investors are buying OvaScience stock?

OVAS stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for OvaScience.

How do I buy shares of OvaScience?

Shares of OVAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OVAS stock can currently be purchased for approximately $0.97.

How big of a company is OvaScience?

OvaScience has a market capitalization of $35.40 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-50,970,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. OvaScience employs 36 workers across the globe.

How can I contact OvaScience?

OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for OvaScience (OVAS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe OVAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.